UCB To Divest Its Neurology And Allergy Business In China
Aug 26 (Reuters) -UCB SA UCB.BR:
UCB TO DIVEST ITS MATURE NEUROLOGY AND ALLERGY BUSINESS IN CHINA, INCLUDING KEPPRA®, VIMPAT®, NEUPRO®, ZYRTEC®
UCB TO DIVEST ITS MATURE NEUROLOGY AND ALLERGY BUSINESS IN CHINA, INCLUDING KEPPRA®, VIMPAT®, NEUPRO®, ZYRTEC®, XYZAL® AND ZHUHAI MANUFACTURING SITE TO CBC GROUP AND MUBADALA INVESTMENT
DIVESTITURE FOR AN AMOUNT OF US$680 MILLION
TRANSACTION IS EXPECTED TO CLOSE IN Q4 2024
DOES NOT IMPACT UCB'S FINANCIAL GUIDANCE FOR 2024
FOR 2025 AND SUBJECT TO CLOSING, A MARGINAL DILUTION OF ADJUSTED EBITDA MARGIN IS ANTICIPATED
ADJUSTED EBITDA MARGIN FOR 2025 IS UNCHANGED EXPECTED AT LOW END OF RANGE OF LOW TO MID-THIRTIES IN PERCENT OF REVENUE
Source text shorturl.at/7ZHjL
Further company coverage: UCB.BR
(Gdansk Newsroom)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
